1. Carioli G, Malvezzi M, Bertuccio P, et al. European cancer mortality predictions for the year 2021 with focus on pancreatic and female lung cancer. Ann Oncol 2021; 32: 478-487.
2.
Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics. Cancer J Clin 2021; 71: 7-33.
3.
NCCN, Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma version 2.2023. Available from: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf (accessed: 09.10.2023).
4.
Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006; 13: 1035-1046.
5.
Callery MP, Chang KJ, Fishman EK, et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 2009; 16: 1727-1733.
6.
Katz MHG, Marsh R, JHerman JM, et al. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol 2013; 20: 2787-2795.
7.
Gemenetzis G, Groot VP, Blair AB, et al. Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection. Ann Surg Oncol 2019; 270: 340.
8.
Xu X, Wu Q, Wang Z, Zheng S, Ge K, Jia C. Meta-analysis of FOLFIRINOX regimen as the first-line chemotherapy for locally advanced pancreatic cancer and borderline resectable pancreatic cancer. Clin Exp Med 2019; 19: 149-157.
9.
Jung JH, Song C, Jung IH, et al. Induction FOLFIRINOX followed by stereotactic body radiation therapy in locally advanced pancreatic cancer. Front Oncol 2022; 12: 1050070.
10.
Janssen QP, van Dam JL, Doppenberg D, et al. FOLFIRINOX as initial treatment for localized pancreatic adenocarcinoma: a retrospective analysis by the Trans-Atlantic Pancreatic Surgery Consortium. JNCI 2022; 114: 695-703.
11.
Suker M, Nuyttens JJ, Eskens FALM, et al. Efficacy and feasibility of stereotactic radiotherapy after folfirinox in patients with locally advanced pancreatic cancer (LAPC-1 trial). EClinicalMedicine 2019; 17: 100200.
12.
Eshmuminov D, Aminjonov B, Palm RF, et al. FOLFIRINOX or gemcitabine-based chemotherapy for borderline resectable and locally advanced pancreatic cancer: a multi-institutional, patient-level, meta-analysis and systematic review. Ann Surg Oncol 2023; 30: 4417-4428.
13.
Krishnan S, Rana V, Janjan NA, et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 2007; 110: 47-55.
14.
Tchelebi LT, Lehrer EJ, Trifiletti DM, et al. Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): an international systematic review and meta-analysis. Cancer 2020; 126: 2120-2131.
15.
Dohopolski MJ, Glaser SM, Vargo JA, Balasubramani GK, Beriwal S. Stereotactic body radiotherapy for locally-advanced unresectable pancreatic cancer – patterns of care and overall survival. J Gastrointest Oncol 2017; 8: 766.
16.
Chuong M, Lee P, Low D, et al. Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: a multi-center, open-label phase 2 study. Radiother Oncol 2024; 191: 110064.
17.
Massaccesi M, Cusumano D, Boldrini L, et al. A new frontier of image guidance: organs at risk avoidance with MRI-guided respiratory-gated intensity modulated radiotherapy: technical note and report of a case. J Appl Clin Med Phys 2019; 20: 194-198.
18.
Herman JM, Chang DT, Goodman KA, et al. Phase 2 multi- institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer 2015; 121: 1128-1137.
19.
Hill CS, Rosati L, Wang H, et al. Multiagent chemotherapy and stereotactic body radiation therapy in patients with unresectable pancreatic adenocarcinoma: a prospective nonrandomized controlled trial. Pract Radiat Oncol 2022; 12: 511-523.
20.
Katz MHG, Shi Q, Meyers JP, et al. Alliance A021501: preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas. J Clin Oncol 2021; 39: 377-377.
21.
Ghorani E, Wong HH, Hewitt C, Calder J, Corrie P, Basu B. Safety and efficacy of modified FOLFIRINOX for advanced pancreatic adenocarcinoma: a UK single-centre experience. Oncology 2015; 89: 281-287.
22.
Tong H, Fan Z, Liu B, Lu T. The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis. Sci Rep 2018; 8: 8666.
23.
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (ver- sion 1.1). Eur J Cancer 2009; 45: 228-247.
24.
Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality- of-life instrument for use in international clinical trials in oncology. JNCI 1993; 85: 365-376.
25.
Fitzsimmons D, Johnson CD, George S, et al. Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. Eur J Cancer 1999; 35: 939-941.
26.
EORTC, Common Terminology Criteria for Adverse Events (CTCAE). Available from: https://www.eortc.be/services/doc/ctc/ctcae_4.03_ 2010-06-14_quickreference_5x7.pdf. (accessed: 09.10.2023).
27.
R Core Team. R: a language and environment for statistical computing. Available from: https://www.scirp.org/reference/ReferencesPapers?ReferenceID=1787696.
28.
Seshan VE. Clinfun: clinical trial design and data analysis functions. R package version 2018; 1.
29.
Barenboim A, Lahat G, Geva R, et al. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: an intention to treat analysis. Eur J Surg Oncol 2018; 44: 1619-1623.
30.
Van Veldhuisen E, van den Oord C, Brada LJ, et al. Locally advanced pancreatic cancer: work-up, staging, and local intervention strategies. Cancers 2019; 11: 976.
31.
Morak MJM, Richel DJ, van Eijck CHJ, et al. Phase II trial of Uracil/Tegafur plus leucovorin and celecoxib combined with radiotherapy in locally advanced pancreatic cancer. Radiother Oncol 2011; 98: 261-264.
32.
Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed- effects models using lme4. J Stat Softw 2015; 67: 1-48.
33.
Kuznetsova A, Brockhoff PB, Christensen RHB. lmerTest package: tests in linear mixed effects models. J Statistic Software 2017; 82: 1-26.
34.
Wickham H. ggplot2: elegant graphics for data analysis. Springer- Verlag, New York 2009.
35.
Kassambara A, Kosinski M, Biecek P, Fabian S. Survminer: drawing survival curves using ‘ggplot2. R package version 0.3 2017; 1.
36.
Rahib L, Wehner MR, Matrisian LM, Nead KT. Estimated projection of US cancer incidence and death to 2040. JAMA Network Open 2021; 4: e214708-e214708.
37.
Teriaca MA, Loi M, Suker M, Eskens FALM, van Eijck CHJ, Nuyttens JJ. A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): long-term outcome. Radiother Oncol 2021; 155: 232-236.
38.
Reyngold M, O’Reilly EM, Varghese AM, et al. Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer. JAMA Oncol 2021; 7: 735-738.
39.
Chang D. Phase III FOLFIRINOX (mFFX) +/– SBRT in locally advanced pancreatic cancer (NCT01926197). Available from: https://clinicaltrials.gov/ct2/show/NCT01926197 (accessed: 09.10.2023).
40.
Kunzmann V, Siveke JT, Algül H, et al. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol 2021; 6: 128-138.
41.
Fietkau R, Ghadimi M, Grützmann R, et al. Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: first results of the CONKO-007 trial. J Clin Oncol 2022; 40: 4008-4008.
42.
Yoo C. mFOLFIRINOX with or without stereotactic body radiotherapy in locally advanced pancreatic adenocarcinoma (SABER) (NCT04986930). Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04986930 (accessed: 04.03.2024).
43.
Chen I. Nivolumab, ipilimumab and chemoradiation in pancreatic cancer. (LAPTOP) (NCT04247165). Available from: https://clinicaltrials.gov/study/NCT04247165 (accessed: 04.03.2024).
44.
Oar A. MFOLFIRINOX and stereotactic radiotherapy (SBRT) for pancreatic cancer with high risk and locally advanced disease (MASTERPLAN) (NCT04089150). Available from: https://clinicaltrials.gov/study/NCT04089150 (accessed: 04.03.2024].
45.
Dunlap N. Effects of folfirinox and stereotactic body radiation therapy for advanced pancreatic cancer (BCC-RAD-13) (NCT02128100). Available from: https://clinicaltrials.gov/study/NCT02128100 (accessed: 04.03.2024).
46.
Kim H. Stereotactic body radiotherapy and focal adhesion kinase inhibitor in advanced pancreas adenocarcinoma (NCT04331041). Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04331041 (accessed: 04.03.2024).
47.
Portalès F. Sequential treatment with GEMBRAX and then FOLFIRINOX followed by stereotactic MRI-guided radiotherapy in patients with locally advanced pancreatic cancer (GABRINOX-ART) (NCT04570943). Available from: https://www.clinicaltrials.gov/study/NCT04570943 (accessed: 04.03.2024).
48.
Therapeutics G. Phase 2b study of GC4711 in combination with SBRT for nonmetastatic pancreatic cancer (NCT04698915). Available from: https://clinicaltrials.gov/study/NCT04698915 (accessed: 04.03.2024).
49.
Viewray Inc. Locally advanced pancreatic cancer treated with ABLAtivE stereotactic MRI-guided adaptive radiation therapy (LAP-ABLATE) (NCT05585554). Available from: https://clinicaltrials.gov/study/NCT05585554 (accessed: 04.03.2024).